Wan, Hailong
Wen, Binhong
Wang, Xueying
Wang, Junfen
Zhang, Yunliang
Ning, Tao
Duan, Binhong
Li, Yufang
Feng, Wei
Zhang, Xia
Cui, Nan
Ji, Linong
Clinical trials referenced in this document:
Documents that mention this clinical trial
1102-P: High vs. Standard Starting Dose of Insulin Glargine 100 U/ml in Patients with Overweight/Obesity and Type 2 Diabetes Uncontrolled with Oral Antidiabetic Drugs in China: A Multicenter, Open-Label Randomized Controlled Trial
https://doi.org/10.2337/db19-1102-p
Effect of Baseline Characteristics on Hypoglycaemia Risk with Insulin Glargine 100 U/mL: Post Hoc Analysis of the BEYOND 7 Study
https://doi.org/10.1007/s13300-021-01112-z
Funding for this research was provided by:
Sanofi China Investment Company
Article History
Received: 10 June 2021
Accepted: 30 June 2021
First Online: 21 July 2021